Drug Profile
Ponsegromab - Pfizer
Alternative Names: PF 06946860Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Appetite stimulants; Heart failure therapies; Monoclonal antibodies
- Mechanism of Action Growth differentiation factor 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cachexia; Heart failure
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Cachexia(In volunteers, In adults) in USA (SC, Injection)
- 07 Jul 2023 Pfizer completes a phase I pharmacokinetics and safety trial in Healthy volunteers in China (SC) (NCT05685264)
- 14 Apr 2023 Safety, Efficacy and pharmacokinetic data from a phase I trial in cachexia advanced cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)